Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06283498
Other study ID # DO612574A
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date November 10, 2023
Est. completion date July 2026

Study information

Verified date October 2023
Source InMode MD Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder The main questions it aims to answer are: •Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. [Time Frame: 3 months] Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis. Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 20
Est. completion date July 2026
Est. primary completion date November 2025
Accepts healthy volunteers No
Gender Female
Age group 21 Years to 80 Years
Eligibility Inclusion Criteria: - Age 21-80 years old, inclusive - Subject is willing to provide Informed Consent, is geographically stable, understands the requirements for completing the bladder diary and is willing to comply with the required diary, follow-up visits, and testing schedules. - Urinary incontinence, predominant urgency incontinence for at least one episode on a 3-days diary. - Reporting at least "moderate bother" on Item 2 on the UDI, "Do you experience a strong feeling of urgency to empty your bladder" (on new patient paperwork) - >8 micturitions and >3 urgency episodes per 24 hours on a 3-day bladder diary (see Appendix 2) - 1 UUI episode on a 3-day bladder diary (see Appendix 2) - Not currently taking anti-muscarinic or beta3 agonist therapy (after at least a 2-week wash-out period) - Post-void residual (PVR) = 100 ml NOTE: it may include Subjects with a single PVR of >100 ml followed by two consecutive PVR measurements of =100 ml in the study. We will record the final acceptable PVR measurement in the data. - Ability and willingness to self-catheterize in case this is necessary. - With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with a failure rate of less than 1% per year when used consistently and correctly from screening until the last follow up Exclusion Criteria: - Pacemaker or internal defibrillator, or any other metallic or electronic implant anywhere in the body. - Any permanent implant or an injected chemical substance in the treatment area. - Superficial areas that have been injected with HA/collagen/fat injections or other augmentation methods with bio-material during last 6 months. - Current or history of cancer, or current condition of any other type of cancer, or premalignant moles. - Severe concurrent conditions, such as cardiac disorders, sensory disturbances, epilepsy, uncontrolled hypertension, and liver or kidney diseases. - Pregnancy, the intention of pregnancy and nursing. - Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, autoimmune disorders, or use of immunosuppressive medications. - Patients with a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen. - Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization. - Any active condition in the treatment area, such as sores, eczema, and rash. - History of vaginal disorders, keloids, abnormal wound healing. - History of bleeding coagulopathies or use of anticoagulants in the last 10 days, as per the practitioner's discretion. - Non-English speakers - Severely impaired mobility or cognition - Spinal cord injury or advanced/severe neurologic condition including Multiple Sclerosis, Parkinson's Disease - Repair of pelvic organ prolapse or incontinence procedure in the previous 6 months - Ongoing complications of prior anti-incontinence surgery - Received intravesical botulinum injection within the previous 12 months - History of an implanted nerve stimulator for incontinence - History of prior sling or vaginal mesh placement, - Previous diagnosis of interstitial cystitis, bladder cancer, or chronic pelvic pain - Current participation in any other conflicting interventional or OAB treatment study - Planning to become pregnant during the study period. - Pelvic radiation, history of pelvic radiation - Subject with 24-hour total urine volume voided greater than 3,000 ml as measured at screening period. - Active urinary tract or vaginal infection - Anatomical conditions that would prevent the introduction and use of the device, in such as significant pelvic organ prolapse, - Current hydronephrosis or hydroureter - Bladder outflow obstruction - Active pelvic organ malignancy - Urethral obstruction - Urinary retention or prolonged catheter use - Less than 12 months post-partum or currently pregnant or plan to become pregnant in the following 12 months. - Untreated symptomatic urinary tract infection - Unevaluated hematuria - Medical instability - Allergy to anesthetics as Benzocaine/Lidocaine/Tetracaine Cream (BLT Cream) used in the study - Not available for follow-up in 6 months - Participation in other research trials that could influence results of this study

Study Design


Intervention

Device:
Device Morpheus8V
Assigned to be treated using the modified Morpheus8V

Locations

Country Name City State
United States Mickey Karram MD Corona Del Mar California
United States Institute for Female Pelvic Medicine Knoxville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
InMode MD Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in urgency incontinence episodes after 3 month Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. 3 months
Secondary Change in urgency incontinence episodes after 1 month Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes 1 month
Secondary Change in urgency incontinence episodes Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. 6 months
Secondary Change in urgency incontinence episodes Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. 12 months
Secondary Analysis to assess the urinary frequency Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency. 1 month
Secondary Analysis to assess urinary frequency Change from baseline to the end of treatment in a 3-day diary analysis to assess urinary frequency. 3 months
Secondary Analysis to assess the urinary frequency. Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency. [Time Frame: 6 months] 6 months
Secondary Analysis to assess the urinary frequency. Change from baseline to the end of treatment in a 3-day diary analysis to assess the urinary frequency. 12 months
Secondary Assessment of the impact of the treatment on Overactive Bladder symptoms Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score > 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence.
The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.
1 month
Secondary Assessment of the impact of the treatment on Overactive Bladder symptoms Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score > 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence.
The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.
3 months
Secondary Assessment of the impact of the treatment on Overactive Bladder symptoms Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score > 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence.
The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.
6 months
Secondary Assessment of the impact of the treatment on Overactive Bladder symptoms Measured by the Incontinence Impact Questionnaire Total Score. Normative values for a general population, 10% of whom scored above 4.8 on IIQ-7. Values obtained from patients with severe incontinence indicate that a score > 70 on the IIQ signifies a poor QOL. Lower scores on IIQ-7 may identify more females who are bothered by urinary incontinence. 7 items are divided into four domains (physical activity, travel, social relationships, emotional health). Item-level scores are rated on a four-point Likert scale (where 0=not at all and 3=greatly), determined by the self-reported impact of symptoms related to urinary incontinence.
The average score of items responded to is calculated. The average, which ranges from 0 to 3, is multiplied by 33 1/3 to put scores on a scale of 0 to 100.
12 months
Secondary Patient-reported Pain assessment The subject will be asked to rate the severity from 0 to 10, with 0 equaling no symptoms and 10 equaling the worst possible symptoms. A number is obtained by measuring up to the point the subject has indicated. treatment procedure
Secondary Patient-reported outcome measure Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome. 1 month
Secondary Patient-reported outcome measure Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome. 3 months
Secondary Patient-reported outcome measure Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome. 6 months
Secondary Patient-reported outcome measure Patient perception of bladder condition and device acceptance measured by Patient Satisfaction Questionnaire. 6 points Likert scale, grading from 0 to 5. A lower score indicates a better outcome. 12 months
See also
  Status Clinical Trial Phase
Completed NCT02540707 - Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes Phase 4
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Not yet recruiting NCT06438861 - Role of Combination Therapy in Women With Refractory Overactive Bladder N/A
Completed NCT01114412 - Basic Sensations Coming From the Bladder
Recruiting NCT06045728 - Telerehabilitation for Overactive Bladder Syndrome in Obese Women N/A
Recruiting NCT03952299 - Oxybutynin for Post-surgical Bladder Pain and Urgency Phase 3
Active, not recruiting NCT03758235 - Overactive Bladder Syndrome: Incobotulinumtoxin Versus Onabotulinumtoxin Phase 3
Completed NCT01912885 - Comparison of Posterior Tibial Nerve Electrical Stimulation Protocols for Overactive Bladder Syndrome N/A
Completed NCT04300400 - Treatment of the Overactive Bladder Syndrome: A Delphi Study
Recruiting NCT04982120 - Use of Repris Needle in Bladder Injection N/A
Completed NCT06123364 - Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder N/A
Recruiting NCT06088394 - Effect of Acupuncture Augmented With Pelvic Floor Exercises on Overactive Bladder N/A
Recruiting NCT05221021 - Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome Phase 4
Terminated NCT04256876 - TTNS Versus Sham Therapy for Children With iOAB (TaPaS Part I) N/A
Not yet recruiting NCT03331081 - Effects of Bladder Training and Pelvic Floor Muscle Training on the Symptomatology of Overactive Bladder Syndrome N/A
Recruiting NCT04873037 - BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder N/A
Completed NCT02024945 - Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome Phase 4
Completed NCT00546637 - Fesoterodine "add-on" Male Overactive Bladder Study Phase 3
Not yet recruiting NCT06143397 - Effect of TTNS and PNS on Neurogenic Overactive Bladder Symptoms in Female Patients With Multiple Sclerosis. N/A
Recruiting NCT03044912 - Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan Phase 3